首页> 美国卫生研究院文献>Springer Open Choice >The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes
【2h】

The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes

机译:基于前1000个诊断小组和外显子组的沙特阿拉伯遗传疾病概况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we report the experience of the only reference clinical next-generation sequencing lab in Saudi Arabia with the first 1000 families who span a wide-range of suspected Mendelian phenotypes. A total of 1019 tests were performed in the period of March 2016–December 2016 comprising 972 solo (index only), 14 duo (parents or affected siblings only), and 33 trio (index and parents). Multigene panels accounted for 672 tests, while whole exome sequencing (WES) represented the remaining 347 tests. Pathogenic or likely pathogenic variants that explain the clinical indications were identified in 34% (27% in panels and 43% in exomes), spanning 279 genes and including 165 novel variants. While recessive mutations dominated the landscape of solved cases (71% of mutations, and 97% of which are homozygous), a substantial minority (27%) were solved on the basis of dominant mutations. The highly consanguineous nature of the study population also facilitated homozygosity for many private mutations (only 32.5% of the recessive mutations are founder), as well as the first instances of recessive inheritance of previously assumed strictly dominant disorders (involving ITPR1, VAMP1, MCTP2, and TBP). Surprisingly, however, dual molecular diagnosis was only observed in 1.5% of cases. Finally, we have encountered candidate variants in 75 genes (ABHD6, ACY3, ADGRB2, ADGRG7, AGTPBP1, AHNAK2, AKAP6, ASB3, ATXN1L, C17orf62, CABP1, CCDC186, CCP110, CLSTN2, CNTN3, CNTN5, CTNNA2, CWC22, DMAP1, DMKN, DMXL1, DSCAM, DVL2, ECI1, EP400, EPB41L5, FBXL22, GAP43, GEMIN7, GIT1, GRIK4, GRSF1, GTRP1, HID1, IFNL1, KCNC4, LRRC52, MAP7D3, MCTP2, MED26, MPP7, MRPS35, MTDH, MTMR9, NECAP2, NPAT, NRAP, PAX7, PCNX, PLCH2, PLEKHF1, PTPN12, QKI, RILPL2, RIMKLA, RIMS2, RNF213, ROBO1, SEC16A, SIAH1, SIRT2, SLAIN2, SLC22A20, SMDT1, SRRT, SSTR1, ST20, SYT9, TSPAN6, UBR4, VAMP4, VPS36, WDR59, WDYHV1, and WHSC1) not previously linked to human phenotypes and these are presented to accelerate post-publication matchmaking. Two of these genes were independently mutated in more than one family with similar phenotypes, which substantiates their link to human disease (AKAP6 in intellectual disability and UBR4 in early dementia). If the novel candidate disease genes in this cohort are independently confirmed, the yield of WES will have increased to 83%, which suggests that most “negative” clinical exome tests are unsolved due to interpretation rather than technical limitations.Electronic supplementary materialThe online version of this article (doi:10.1007/s00439-017-1821-8) contains supplementary material, which is available to authorized users.
机译:在这项研究中,我们报告了沙特阿拉伯唯一的参考临床下一代测序实验室的经验,该实验室具有范围广泛的孟德尔表型的前1000个家庭。在2016年3月至2016年12月期间,共进行了1019次测试,包括972个独奏(仅索引),14个二重奏(仅父母或受影响的兄弟姐妹)和33个三重奏(索引和父母)。多基因组占672个测试,而全外显子组测序(WES)代表其余347个测试。可以解释临床症状的致病性或可能致病性变体的比例为34%(小组中为27%,外显子组为43%),涵盖279个基因,包括165个新变体。虽然隐性突变在解决病例中占主导地位(71%的突变,其中97%是纯合的),但基于显性突变却解决了少数(27%)的问题。研究人群的高度血缘性质也促进了许多私人突变的纯合性(仅隐性突变的32.5%是建立者),以及先前假定的严格显性疾病(涉及ITPR1,VAMP1,MCTP2,和TBP)。但是,令人惊讶的是,仅在1.5%的病例中观察到了双分子诊断。最后,我们在75个基因中遇到了候选变体(ABHD6,ACY3,ADGRB2,ADGRG7,AGTPBP1,AHNAK2,AKAP6,ASB3,ATXN1L,C17orf62,CABP1,CCDC186,CCP110,CLSTN2,CNTN3,CNTN5,CTNNA21,CWC22,D ,DMXL1,DSCAM,DVL2,ECI1,EP400,EPB41L5,FBXL22,GAP43,GEMIN7,GIT1,GRIK4,GRSF1,GTRP1,HID1,IFNL1,KCNC4,LRRC52,MAP7D3,MCTP2,MED26,MPP7,MTDH,MRPS35 ,NPAT,NRAP,PAX7,PCNX,PLCH2,PLEKHF1,PTPN12,QKI,RILPL2,RIMKLA,RIMMS2,RNF213,ROBO1,SEC16A,SIAH1,SIRT2,SLAIN2,SLC22A20,SMDT1,SRRT,SSTR1,ST20,SYT9, ,VAMP4,VPS36,WDR59,WDYHV1和WHSC1)以前未与人的表型相关联,因此可以加快出版后的配对过程。这些基因中的两个在一个以上具有相似表型的家族中被独立突变,这证实了它们与人类疾病的联系(智力障碍中的AKAP6和早期痴呆症中的UBR4)。如果该队列中的新候选疾病基因得到独立证实,那么WES的产率将提高到83%,这表明大多数“阴性”临床外显子组测试由于解释而不是技术限制而无法解决。电子补充材料本文(doi:10.1007 / s00439-017-1821-8)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号